Summary We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70% of progenitor cells in vitro (ID70) was similar to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in patients, suggesting a predictive value for the assay.
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Keywords: carzelesin; tallimustine; clonogenic tests; toxicology Phase I clinical trials remain pivotal in the development of new anticancer drugs, but more refined methods are needed to minimize the number of patients treated with inactive dosages. Traditionally, the starting dose for phase I studies corresponds to one-tenth of the mouse LD10, with subsequent dose escalations according to a modified Fibonacci scheme, however methods to reduce the number of dose levels have been proposed in recent years. One of them, the 'pharmacologically guided dose escalation' method, relies on the observation that for many (but not all) drugs plasma levels in mice at the LDIO are similar to those found in humans at the MTD, and that similar AUC values in mice and humans will produce similar toxic effects (Davis et al, 1988; Collins et al, 1990; Gianni et al, 1990) . Nevertheless, because of interspecies variations in schedule dependency, tissue distribution and steepness of the slope of the toxicity vs concentration curve, the planning and performance of phase I trials cannot be based on animal experiments only, but should also be based on in vitro data on human tissues (EORTC Pharmacokinetics and Metabolism Group, 1987) . The toxicity of new substances against human haemopoietic tissue has been assessed in clonogenic tests on bone marrow cells after exposure to the drug under study. A number of agents were tested by this method, which proved to predict myelotoxicity reliably for many substances (Du et al, 1990 (Du et al, , 1991 . These tests can also predict the rate of increase in myelotoxicity during dose escalation as well as the interpatient variability (Parchment et al, 1993) .
We decided to use a similar type of test to study DNA minor groove alkylators, a family of drugs for which phase MI/I evaluations have recently been started. These drugs appear to display a high DNA sequence specificity of alkylation (Broggini et al, 1991; D'Incalci, 1994) , which in turn could lead to a higher specificity of Figure 1 Chemical structure of the distamycin derivatives used the anti-tumour effect. Members of this family are carzelesin, which is a CC-1065 derivative, and the distamycin derivatives, some of which have been shown to possess anti-tumour activity in several models (Pezzoni et al, 1991; Li et al, 1992; D'Alessio et al, 1994) . In order to compare the in vitro activity of these substances, we determined their cytotoxicity in tumour cell lines and their toxic effects on human haemopoietic tissue. The latter are usually studied on human bone marrow cells, but these are difficult to obtain in large amounts. Given the similarity between bone marrow (BM) and human cord blood-derived haematopoietic cells (Hows et al, 1992) , we developed a model based on cord blood (hCB) cells and used it, after validation, to compare the myelotoxicity of carzelesin and of four distamycin derivatives. After thawing, cells were exposed for 1 h to the drug to be tested at 37'C in IMDM. Cells were then washed twice with medium before being plated on clonogenic assays. The experiments with tallimustine were performed on both BM and hCB, and the other drugs were tested on hCB cells only. Tallimustine was also tested in continuous exposure, by plating BM cells with different concentrations of the drug, which then remained in the medium for the subsequent 2 weeks. For each drug, a first set of 3-6 experiments was set up at concentrations ranging over four logs, while in a second set of 3-6 experiments doses were chosen within the ID30-ID 9 range to fine tune the dose-response curve at the critical concentrations.
MATERIALS AND METHODS

Clonogenic assays
Clonogenic assays were performed according to previously described methods (Coutinho et al, 1993) . Briefly, cells were plated in methylcellulose and IMDM, supplemented with 30% FCS, 1% bovine serum albumin (BSA), 10% conditioned medium from the bladder carcinoma cell line 5637 and 2 IU of recombinant erythropoietin. Triplicate cultures were prepared with a final concentration of 1 or 2 x 105 MNC ml in 4-well tissue culture plates (Falcon). The plates were incubated for 14 days at 37°C in 5% carbon dioxide and fully humidified air. Colonies were scored on an inverted microscope at 7 days (GM-CFCd7 and CFU-E) and at 14 days (GM-CFCdl4, BFU-E and Mix-CFC) according to established criteria: GM-CFC contain at least 50 cells, while a CFC-E is a group of at least five haemoglobinized cells. BFU-E are composed of at least three clusters of haemoglobinized cells near to each other. Mix-CFC are colonies containing both myeloid and erythroid components (Coutinho et al, 1993; Lewis et al, 1994) .
Cell line experiments
Monolayer cultures of human colon adenocarcinoma LoVo (Drewinko et al, 1976) and HT-29 (Fogh and Trempe, 1975) were maintained in Ham's F12 medium supplemented with 1% vitamins (Vitamins BME solution), 2mM L-glutamine and 10% FCS. The human lymphoblastic leukaemia cell line CEM (Beck et al, 1979; Danks et al, 1987) was maintained in minimal essential medium (MEM) supplemented with 10% inactivated FCS and 1% vitamin, and the chronic myeloid leukaemia EM-2 (Keating, 1987) and Tcell leukaemia Jurkatt (Weiss et al 1985) human cell lines were grown in RPMI supplemented with 10% FCS, 2 mM L-glutamine, penicillin and streptomycin.
The drug concentrations required for 70% cell growth inhibition (IC70) were determined for LoVo and HT-29 cells using a singlecell plating technique. Exponentially growing cells were seeded 48 h before treatment and then exposed to drugs for 1 h. The medium was removed and cells were incubated in drug-free medium. The number of adherent colonies (at least 50 cells) was determined by manual counting on a light microscope after 8-10 days of incubation at 37°C in 5% carbon dioxide. In vitro drug sensitivity against EM2, Jurkatt and CEM cells was evaluated by counting surviving cells. Exponentially growing cells were seeded in test tubes (lx105 cells ml-1, 2 ml per tube) in the presence of various concentrations of drug. The incubation mixture was kept at 37°C for 1 h, and cells were then washed and incubated for 48 h in drug-free medium. The inhibition of cell growth was evaluated by counting surviving cells with a Coulter counter.
The antiproliferative activity of the drugs was calculated from dose-response curves and expressed as IC70 (dose causing the inhibition of cell growth in treated cultures relative to untreated controls). Analysis of data and statistics Dose-response curves were produced by computer using a standard software program (Excel version 5.0). The concentration inhibiting the growth of 70% of CFC (ID70) was extrapolated from the curves (Figure 2) , and the ID70 on GM-CFC d14 was taken as an index of myelotoxicity. For each drug and progenitor type, the slope of the dose-response curve was also calculated. This parameter, which others have called 'rate of increase in myelotoxicity' (Parchment et al, 1993) (Friedman, 1981) .
RESULTS
Initial studies were performed on BM cells to evaluate the concentration-cytotoxicity curve of 1 h exposure to tallimustine in a range of drug concentrations between 100 and 400 ng ml-'. Linearity was observed in the range between 20 and 200 ng ml-' (Figure 3) . Subsequent experiments were set up with tallimustine on both BM and hCB cells at doses ranging from 20 to 200 ng ml-', constituting the linear part of the curve. Figure 3 shows a comparison between the toxicity of tallimustine (1 h exposure) for BM and hCB cells on GM-CFCdl4. Even though a remarkable variability was observed, similar sensitivity to the drug was observed for both cell sources, the median ID70 for GM-CFCdl4 being 135 ng ml-' (range 105-240 ng ml-') for BM and 165 ng ml-'
(110-235 ng ml-') for hCB.
We then tested, on hCB only, the effect of 1 h exposure to the three other distamycin derivatives, carzelesin and L-PAM. Cell inhibition was determined for all progenitors assessable by this assay, i.e. GM-CFCd7 and d14, CFU-E, BFU-E and CFU-mix. For all the types of cells, the ID70 was calculated, except for CFU-mix, which were found in low numbers (even in controls) and hence did not allow any analysis. Table 1 reports the median ID70 of each drug against any progenitor type. Overall, all drugs appear to be more toxic against more differentiated progenitors (CFCd7) than against more immature progenitors (CFCdl4). The differences observed, however, were not statistically significant, with the exception of carzelesin and L-PAM. Carzelesin was the most potent drug. Tallimustine was the most potent among distamycin analogues, while L-PAM had an intermediate potency between FCE25450 and FCE28102.
The cytotoxicity of different exposure times was studied only for tallimustine. The ID70 for GM-CFCd7 from hCB was 130 ng ml-' (range 110-240 ng ml-') for 1 h exposure and 13 ng ml' (4-28 ng ml-') for continuous exposure; for GM-CFCdl4, the corresponding figures were 135 ng ml-' (range 105-240 ng ml-') and 16 ng ml-' (2-32 ng ml-') respectively. It appears that, for this drug, continuous exposure is approximately ten times more myelotoxic than a 1-h exposure, suggesting that the myelotoxicity is schedule dependent. reported in Table 3 . Acute leukaemia cell lines were the most sensitive, while the response of the other cell lines was more variable. Table 4 reports the in vitro therapeutic index of each drug. It appears that carzelesin, the most potent compound, has the best in vitro therapeutic index. In fact, the dose of carzelesin that is toxic against tumour cell lines is approximately 16 times lower than the one that is toxic against human haematopoietic cells or, in other words, the cytotoxic dose is 16 times lower than the myelotoxic one. For the other compounds, differences between cytotoxic and myelotoxic doses are not so strikingly different.
DISCUSSION
To gain more insight into the characteristics of minor groove alkylators and to optimize the planning of phase I trials with these drugs, we performed myelotoxicity experiments on human haematopoietic tissue, using cord blood as a source of cells. The advantages of this cell source for pharmacological testing are that they are easily obtained and available in abundance. Haematopoietic stem and precursor cells are normally present in fetal blood and were shown to share many features with BM cells (Hows et al, 1992) , although some immunophenotypic and in vitro growth characteristics are not completely superimposable (Hao et al, 1995; Fritsch et al, 1996) . Recently, Leglise et al (1996) demonstrated the equivalence of both stem cell sources for in vitro myelotoxicity tests for several classes of drugs, including anticancer, antibiotic and antiviral drugs. Experiments performed in our laboratory with doxorubicin and other anthracyclines produced very similar results on hCB and on BM (manuscript in preparation). The equivalence of BM and hCB for pharmacology tests is also supported by our results with tallimustine, showing similar median ID70 for the two sources, i.e. 135 ng ml-' (range 105-240 ng ml-') and 165 ng ml (range 110-235 ng ml-') respectively. In addition, the ID70 we obtained with L-PAM for GM-CFC and BFU-E on hCB cells were similar to those reported by other groups on BM cells (Du et al, 1990) . Our results are not in agreement with those of Volpe et al (1992) , who tested tallimustine on BM cells; in their hands, tallimustine was shown to be more toxic than in ours, and erythroid cells appeared to be more sensitive than myeloid progenitors. These discrepancies might not be related to the cell source but to technical differences, such as mode of drug dilution, time of exposure (4 h instead of 1 h), smaller number of experiments and different range of concentrations tested. We have observed an important variability of ID70 on all the progenitors tested because cells from some sources are intrinsically more sensitive to drugs than others. This corresponds to the difference in chemotherapy tolerance seen among patients in the clinic, the cause of which is still mostly unknown, even though differences in intracellular distribution, active cell excretion and integrity of repair mechanisms can be speculated.
To ensure clinically relevant information, we studied the dose-response curve in the range of clinically relevant concentrations (ID30-ID80). For tallimustine, for example, the ID30 is around 100 ng mll and the ID90 is around 300 ng ml-', so that the testing of concentrations much below or above this range would not yield much information. The estimation of the toxic drug levels could become very helpful in the setting of pharmacologically guided dose escalation, whereby the goal would become the attainment of plasma concentrations similar to those achieved in animals at toxic doses and within the range of those found to be cytotoxic in clonogenic tests (Du et al, 1995) . The drug concentrations defined in our experiments are in agreement with those achieved in humans: the ID70 range found for tallimustine against myeloid progenitors (90-235 ng ml-') is in the range (104-189 ng ml') of those reported in four patients 1 h after administration of doses near the MTD (Sessa et al, 1994) . A similar trend was also seen for carzelesin (in vitro 1.7-6.3 ng ml-', in humans 1-2 ng ml-') (Wolff et al, 1996) and L-PAM (in vitro 590-2100 ng ml-', in humans 100-800 ng ml-' at a dose below the MTD) (Zucchetti et al, 1988) . A similar in vivo-in vitro correlation for myelotoxicity between concentrations active on clonogenic tests and plasma concentrations achieved in phase I studies was found with other compounds such as pyrazolacridine (Parchment et al, 1994; Rowinsky et al, 1995) .
Clonogenic tests could also help to define which component of the drug exposure (peak, AUC, time above a threshold concentration) is the most important for toxicity. For tallimustine, all progenitors were killed when exposed in vitro for 1 h at 400 ng ml-' or higher. Based on our data showing that a continuous exposure of 40 ng ml-' is as toxic as 400 ng m1-for 1 h, we believe that AUC and not the time above a critical concentration is the main determinant of toxicity.
The pattern of toxicity of a drug on haemopoietic cells in vitro could be useful for predicting the pattern of myelotoxicity in humans. In the process of blood cell differentiation, a common stem cell capable of autoreplication gives rise to a lymphatic and a myeloid precursor. The latter, which corresponds in vitro to the long-term culture-initiating cell (LTC-IC), generates progenitor cells of granulocytes and macrophages (GM-CFCdl4), erythrocytes (BFU-E) and megakaryocytes (BFU-Meg), which are clonogenic and hence recognizable in vitro. These progenitors then differentiate into the final mature blood elements through an intermediate step of cells (Lewis et al, 1994) which are still clonogenic (GM-CFCd7, CFC-E and Meg-CFC). Our assay can test myeloid and erythroid clonogenic cells, while the analysis of LTC-IC requires more sophisticated and time-consuming methods based on the long-term culture principle (Hows et al, 1992) . The study of megakaryocyte progenitors would also be relevant for the clinic, but this technique is still insufficiently standardized to be applied.
From our results, we could predict that tallimustine and FCE28102 (which seemed to be more toxic against the myeloid than the erythroid line) would induce, mainly, a selective granulocytopenia, while L-PAM, carzelesin and the other distamycin derivatives would mainly affect the erythroid line. Preliminary clinical data with tallimustine and carzelesin support this hypothesis. Even though anaemia is clinically less relevant and more difficult to evaluate than leucopenia, the difference in the toxic effects on the myeloid and erythroid lines is theoretically interesting as it illustrates how changes in the chemical structure of the alkylating moiety can affect the response of each cell type.
It should be pointed out that the mechanism of cytotoxicity of minor groove binders has still not been fully elucidated. The compounds that have been investigated in greater detail are CC-1065 or its analogues, including carzelesin and the distamycin derivative tallimustine. CC-1065 and its analogues alkylate adenine N3 with a high selectivity for adenine located in the sequence AAAAA or PUNAAA, whereas tallimustine alkylates adenine N3 located in the hexamer TTTTGA. Therefore, even though all these compounds can be classified as DNA minor groove alkylators, it appears that they can hit different DNA sequences, possibly causing function impairment of different genes. Recent studies have in fact shown that both the CC-1065 type of compounds and distamycin derivatives can selectively block the sequence-specific binding of transcription factors, thus impairing the transcription of genes regulated by these proteins. It is then conceivable that different minor groove binders possess different sequence preferences for DNA binding, thereby causing different biological effects, either in terms of their anti-tumour activity or of their toxicity. This could be an explanation for the difference in the pattern of myelotoxicity of tallimustine and carzelesine and of tallimustine and some of the other distamycin derivatives, such as FCE 25450.
For all drugs tested, the less differentiated precursors (GMCFCdl4 and BFU-E) seemed to be less affected than the more mature ones (GM-CFCd7 and CFC-E). The higher resistance to cytostatics could be interpreted as a higher capability of immature cells to repair DNA or, alternatively, be attributed to the smaller proportion of immature cells that are in a proliferative state. We can hypothesize that similar resistance mechanisms could play a role in the different patterns of myelotoxicity in humans, for example tallimustine was shown to cause an early, brief and selective granulocytopenia (Sessa et al, 1994) while carzelesin induced a delayed, long-lasting and cumulative pancytopenia (Wolff et al, 1996) . For tallimustine, we can hypothesize that early precursor cells (i.e. LTC-IC) might be more resistant while clonogenic cells such as GM-CFC are very sensitive to the drug; for carzelesin, the contrary might be true. These issues could be elucidated by the long-term culture system, which could help to define the differentiation step of the haematopoietic process that is most affected by the exposure to a given cytotoxic agent.
Minor-groove alkylators remain a promising field of research. Other distamycin analogues could now enter phase I trials, and data from our clonogenic tests will be useful for selecting the compounds most promising for clinical development. From the results of this study, it appears that the analogue with the best therapeutic index (three times better than tallimustine, approximately nine times better than L-PAM) is the distamycin derivative FCE25450, which bears an a-bromoacrylic group, and its further development in phase I trials should be encouraged. On the other hand, the excellent in vitro therapeutic index of carzelesin has not yet been confirmed in clinical studies, whereby delayed, longlasting and cumulative myelosuppression represents the doselimiting toxicity.
In conclusion, we have shown that valuable predictive information on the myelotoxicity of cytotoxic agents can be obtained by clonogenic assays on human cord blood cells. By comparing new analogues to known drugs, a therapeutic index as well as the starting dose and the magnitude of dose escalations for clinical studies could be suggested.
